Medullary thyroid carcinoma (MTC)
What the FDA labels record as adverse events, each one tied back to the evidence it came from.
What is Medullary thyroid carcinoma (MTC)?
Medullary thyroid carcinoma, a rare tumor of the thyroid C-cells.
The boxed warning most GLP-1s carry (twice-daily exenatide is an exception) traces back to rodent studies, and no rise in human incidence has been shown. Anyone whose own history, or whose family history, includes MTC or MEN-2 should not take these drugs. A serious intake form asks about that; a careless one skips it.
Related reading: GLP-1 Thyroid Cancer Risk: What the Boxed Warning Actually Says
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Medullary thyroid carcinoma (MTC) comes up on this site
Connected terms
Other terms under Side effects
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers